Want to see HK:2496 full AI Analyst Report?
Total Valuation
Wuhan YZY Biopharma Co., Ltd. Class H has a market cap or net worth of HK$916.51M. The enterprise value is HK$809.03M.
Market CapHK$916.51M
Enterprise ValueHK$809.03M
Share Statistics
Wuhan YZY Biopharma Co., Ltd. Class H has 179,479,110 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding179,479,110
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Wuhan YZY Biopharma Co., Ltd. Class H’s return on equity (ROE) is 1.56 and return on invested capital (ROIC) is -117.22%.
Return on Equity (ROE)1.56
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-117.22%
Return on Capital Employed (ROCE)3.44
Revenue Per Employee614.41K
Profits Per Employee-799.36K
Employee Count106
Asset Turnover0.37
Inventory Turnover17.94
Valuation Ratios
The current PE Ratio of Wuhan YZY Biopharma Co., Ltd. Class H is ―. Wuhan YZY Biopharma Co., Ltd. Class H’s PEG ratio is 1.07.
PE Ratio―
PS Ratio21.44
PB Ratio-26.32
Price to FCF-62.16
Price to Operating Cash Flow-7.19
PEG Ratio1.07
Income Statement
In the last 12 months, Wuhan YZY Biopharma Co., Ltd. Class H had revenue of 65.13M and earned -82.54M in profits. Earnings per share was -0.42.
Revenue65.13M
Gross Profit6.17M
Operating Income-87.93M
Pretax Income-82.54M
Net Income-82.54M
EBITDA-83.49M
Earnings Per Share (EPS)-0.42
Cash Flow
In the last 12 months, operating cash flow was -80.39M and capital expenditures -6.37M, giving a free cash flow of -86.76M billion.
Operating Cash Flow-80.39M
Free Cash Flow-86.76M
Free Cash Flow per Share-0.48
Dividends & Yields
Wuhan YZY Biopharma Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.27
52-Week Price Change-50.63%
50-Day Moving Average3.30
200-Day Moving Average4.82
Relative Strength Index (RSI)59.78
Average Volume (3m)76.30K
Important Dates
Wuhan YZY Biopharma Co., Ltd. Class H upcoming earnings date is Mar 26, 2027, TBA (Confirmed).
Last Earnings DateAug 28, 2026
Next Earnings DateMar 26, 2027
Ex-Dividend Date―
Financial Position
Wuhan YZY Biopharma Co., Ltd. Class H as a current ratio of 0.66, with Debt / Equity ratio of -236.77%
Current Ratio0.66
Quick Ratio0.64
Debt to Market Cap0.09
Net Debt to EBITDA-0.33
Interest Coverage Ratio-18.23
Taxes
In the past 12 months, Wuhan YZY Biopharma Co., Ltd. Class H has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Wuhan YZY Biopharma Co., Ltd. Class H EV to EBITDA ratio is -17.06, with an EV/FCF ratio of -63.40.
EV to Sales21.87
EV to EBITDA-17.06
EV to Free Cash Flow-63.40
EV to Operating Cash Flow-66.01
Balance Sheet
Wuhan YZY Biopharma Co., Ltd. Class H has HK$75.98M in cash and marketable securities with HK$138.62M in debt, giving a net cash position of -HK$62.64M billion.
Cash & Marketable SecuritiesHK$75.98M
Total DebtHK$138.62M
Net Cash-HK$62.64M
Net Cash Per Share-HK$0.35
Tangible Book Value Per Share-HK$0.27
Margins
Gross margin is 38.50%, with operating margin of -135.02%, and net profit margin of -126.73%.
Gross Margin38.50%
Operating Margin-135.02%
Pretax Margin-126.73%
Net Profit Margin-126.73%
EBITDA Margin-128.20%
EBIT Margin-135.02%
Analyst Forecast
The average price target for Wuhan YZY Biopharma Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-55.22%
EPS Growth Forecast57.76%